Anthropic Launches Claude Science for Drug Discovery and Ships Claude Sonnet 5

Anthropic unveiled Claude Science, positioning itself as the first frontier lab to treat direct drug development — not just model provision — as a core business line. The effort is anchored by John Jumper, the Nobel-winning co-creator of DeepMind's AlphaFold, signaling serious intent in computational biology and molecular design. Anthropic separately described a related research workbench for computational scientists.

Alongside the science push, Anthropic shipped Claude Sonnet 5 on July 2, pitched as stronger on coding, reasoning and agentic tasks, and rolled out a self-hosted Claude Code gateway for enterprises needing on-prem governance. Claude Sonnet 5 is also landing in Microsoft Foundry on Azure Databricks for compliance-sensitive workflows.

The move sharpens a widening strategic split: while Meta, Microsoft and AWS race to monetize compute and deployment services, Anthropic is betting on vertical scientific value creation. Google DeepMind has long straddled this with Isomorphic Labs, so Anthropic entering drug discovery directly puts the two labs on a collision course in AI-for-science.

All of this unfolds against the backdrop of Anthropic's turbulent week — the Fable 5 suspension and restoration, the CJS framework, and its accusation that Alibaba illicitly distilled Claude's capabilities. Wharton's Ethan Mollick noted that Fable in Claude Code "is capable of really amazing things" but the interface "is not really designed for managing 5+ hour long autonomous tasks." Watch whether Claude Science produces a named drug candidate or partnership, and how enterprises adopt the self-hosted Code gateway.